BrightSpring Health Services, Inc. BTSG

Healthcare SIC 8082 - Services-Home Health Care Services NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Home Health Care Services derived Nasdaq

We are a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. We have a differentiated approach to care delivery, with an integrated and scaled model that addresses critical services that the highest-need and highest-cost patients require. With a focus on Senior and Specialty patients, which includes Behavioral populations, our platform provides pharmacy and provider services (both clinical and supportive care in nature) in lower-cost home and community settings largely to Medicare, Medicaid, and commercially-insured populations. We are an essential part of our nation's health delivery network as a front-line provider of high-quality and cost-effective care to a large and growing number of people, who increasingly require a combination of specialized solutions to enable holistic health care management. Our presence spans all 50 states, we serve over 465,000 patients daily through our approximately 10,500 clinical providers and pharmacists, and our services make a profound impact in the lives and communities of the people we serve.

Last close 60.11 2026-10-23
Market cap $11.89B 2026-06-30 share count
52-week range 30.64 - 73.75

Valuation FY2025 figures against the last close

P/S0.9x
P/E69.1x
P/FCF30.1x
EV/EBITDA39.0x
Dividend yield—
Diluted EPS0.87

Where the revenue comes from as reported in the latest 10-K

Revenue by segment

  • Pharmacy Solutions - Products
  • Provider Services - Services
Revenue by segment, 2 categories over 3 years. The same figures are in the table below. FY2025 Pharmacy Solutions - Products, FY2025: 11.4B (88.7%) 89% Pharmacy Solutions - Products Provider Services - Services, FY2025: 1.5B (11.3%) 11% FY2024 Pharmacy Solutions - Products, FY2024: 8.8B (86.9%) 87% Provider Services - Services, FY2024: 1.3B (13.1%) 13% FY2023 Pharmacy Solutions - Products, FY2023: 6.5B (84.8%) 85% Provider Services - Services, FY2023: 1.2B (15.2%) 15%
Segment FY2025FY2024FY2023
Pharmacy Solutions - Products $11.45B $8.75B $6.52B
Provider Services - Services $1.46B $1.32B $1.17B

As the company reported it, from the “Segment Information - Schedule of Reportable Segments Reconcile of Segment Information (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021
Revenue $12.91B$10.07B$7.69B$6.64B—
Gross profit $1.52B$1.27B$1.14B$1.08B—
SG&A $1.22B$1.16B$1.08B$925.2M—
Operating income $295.3M$108.0M$58.1M$118.9M—
Interest expense $157.3M$190.5M$271.9M$199.8M—
Pre-tax income $137.9M-$95.3M-$213.8M-$81.0M—
Income tax $33.1M$26.4M$31.5M$33.1M—
Net income $189.1M$20.5M-$154.6M-$53.9M—
EPS, basic 0.94-0.09-1.31-0.46—
EPS, diluted 0.87-0.09-1.31-0.46—
Shares, diluted (wtd. avg.) 219.8M193.0M117.9M117.8M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021
Cash and equivalents $88.4M$61.0M$12.4M——
Receivables $989.7M$902.8M$881.6M——
Inventory $815.2M$636.6M$402.8M——
Total current assets $2.89B$1.89B$1.46B——
Property, plant and equipment $204.7M$180.6M$245.9M——
Goodwill $2.55B$2.36B$2.30B$2.58B—
Other intangibles $557.6M$595.2M$881.5M——
Total assets $6.41B$5.93B$5.53B——
Accounts payable $1.22B$923.9M$641.6M——
Short-term debt $52.3M$48.7M$32.3M——
Total current liabilities $1.85B$1.43B$1.25B——
Long-term debt $2.46B$2.56B$3.33B——
Total liabilities $4.53B$4.27B$4.92B——
Retained earnings -$74.6M-$222.2M-$200.3M——
Total equity $1.88B$1.65B$585.4M$754.8M$774.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021
Operating cash flow $490.2M$23.8M$210.8M-$4.7M—
Depreciation and amortisation $71.8M$66.8M$57.3M$55.1M—
Stock-based compensation $70.1M$69.2M$3.9M$3.5M—
Capital expenditure $95.5M$80.9M$73.5M$70.1M—
Investing cash flow -$305.1M-$140.2M-$134.4M$45.4M—
Financing cash flow -$157.9M$164.6M-$76.9M-$73.8M—
Buybacks $43.2M$650.0K$650.0K——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151207.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -5B 0 5B 10B 15B Revenue, FY2022: 6.6B Gross profit, FY2022: 1.1B Net income, FY2022: -53.9M Revenue, FY2023: 7.7B Gross profit, FY2023: 1.1B Net income, FY2023: -154.6M Revenue, FY2024: 10.1B Gross profit, FY2024: 1.3B Net income, FY2024: 20.5M Revenue, FY2025: 12.9B Gross profit, FY2025: 1.5B Net income, FY2025: 189.1M FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2021FY2022FY2023FY2024FY2025
Revenue — $6.64B $7.69B $10.07B $12.91B
Gross profit — $1.08B $1.14B $1.27B $1.52B
Net income — -$53.9M -$154.6M $20.5M $189.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed Item 1.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8082

TickerCompanyMarket capP/ERevenue growth
CHE CHEMED CORP $6.70B 28.0x 4.1%
OPCH Option Care Health, Inc. $4.90B 24.6x 13.0%
AVAH Aveanna Healthcare Holdings, Inc. $2.92B 12.7x 20.2%
ADUS Addus HomeCare Corp $2.27B 23.3x 23.2%
AHCO AdaptHealth Corp. $820.8M — -0.5%